Develops DNA medicines and delivery devices intended to treat or protect people from HPV-associated diseases, cancer and infectious diseases.
Sources
10-K for FY2025, filed Mar 12, 2026
We are a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from…View ↗
We use proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body’s cells can…View ↗
How Do They Make Money?
INOVIO has not generated revenue from product sales; it earns money from license fees, milestone revenue, and collaborative research and development agreements and contracts.
Sources
10-K for FY2025, filed Mar 12, 2026
All of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any…View ↗
Oct 30, 2026FDA grants accelerated approval for VOCERYQ
Approval is for reducing surgery frequency in adults with RRP, and continued approval may depend on confirmatory studies.
Sources
8-K, filed Nov 2, 2026
On October 30, 2026, the Company announced that the FDA has granted accelerated approval for VOCERYQ™ (doruxapapogene ralaplasmid and…View ↗
Shrinking.
Revenue fell 96% in 4 years, from $1.8M in FY2021 to $65.3K in FY2025, about 56% a year.